Literature DB >> 29233542

Natural killer cells and anti-tumor immunity.

Sandra E Nicholson1, Narelle Keating2, Gabrielle T Belz3.   

Abstract

Immune checkpoint inhibitors harness the power of the immune system to fight cancer. The clinical success achieved with antibodies against the inhibitory T cell receptors PD-1 and CTLA4 has focused attention on the possibility of manipulating other immune cells, in particular those involved in innate immunity. Here we review the role of innate lymphoid cells (ILCs) and their contribution to tumor immunity. As the prototypical ILC, the natural killer (NK) cell has an intrinsic ability to detect and kill cancer cells. NK cells are dependent on the cytokine interleukin (IL)-15 for their development and effector activity. We discuss the role of the Suppressor of cytokine (SOCS) proteins in negatively regulating IL-15 and NK cell responses and the potential for targeting these small intracellular regulators as new immune checkpoints.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CIS; Cancer; IL-15; ILCs; NK cells; SOCS proteins; SOCS2

Mesh:

Substances:

Year:  2017        PMID: 29233542     DOI: 10.1016/j.molimm.2017.12.002

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  24 in total

1.  IL-15 regulates fibrosis and inflammation in a mouse model of chronic pancreatitis.

Authors:  Murli Manohar; Hemanth Kumar Kandikattu; Alok Kumar Verma; Anil Mishra
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-09-13       Impact factor: 4.052

Review 2.  Nobiletin as an inducer of programmed cell death in cancer: a review.

Authors:  Jun Huang; Zaoshang Chang; Quzhe Lu; Xuedong Chen; Masoud Najafi
Journal:  Apoptosis       Date:  2022-03-21       Impact factor: 4.677

Review 3.  Targeting of the tumor immune microenvironment by metformin.

Authors:  Zihong Wu; Caidie Zhang; Masoud Najafi
Journal:  J Cell Commun Signal       Date:  2021-10-05       Impact factor: 5.908

4.  Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a KrasLSL-G12D p53LSL-R172H Pdx1-Cre mouse model.

Authors:  Su Hu; Jia Yang; Junjie Shangguan; Aydin Eresen; Yu Li; Quanhong Ma; Vahid Yaghmai; Yuri Velichko; Chunhong Hu; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

5.  Eomes Expression Defines Group 1 Innate Lymphoid Cells During Metastasis in Human and Mouse.

Authors:  Riva Verma; Jun Zhi Er; Ren Wei Pu; Jameelah Sheik Mohamed; Ross A Soo; Harish Mithiran Muthiah; John Kit Chung Tam; Jeak Ling Ding
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

6.  Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71.

Authors:  Wilhelm Salzberger; Gloria Martrus; Kai Bachmann; Hanna Goebels; Leonard Heß; Martina Koch; Annika Langeneckert; Sebastian Lunemann; Karl J Oldhafer; Caroline Pfeifer; Tobias Poch; Laura Richert; Christoph Schramm; Ramez Wahib; Madeleine J Bunders; Marcus Altfeld
Journal:  PLoS One       Date:  2018-07-20       Impact factor: 3.240

Review 7.  IL-27, IL-30, and IL-35: A Cytokine Triumvirate in Cancer.

Authors:  Olena Kourko; Kyle Seaver; Natalya Odoardi; Sameh Basta; Katrina Gee
Journal:  Front Oncol       Date:  2019-10-01       Impact factor: 6.244

8.  Lactic Acid Bacteria from Kefir Increase Cytotoxicity of Natural Killer Cells to Tumor Cells.

Authors:  Takuya Yamane; Tatsuji Sakamoto; Takenori Nakagaki; Yoshihisa Nakano
Journal:  Foods       Date:  2018-03-27

9.  Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.

Authors:  Amy M Buckley; Margaret R Dunne; Maria E Morrissey; Susan A Kennedy; Aoife Nolan; Maria Davern; Emma K Foley; Niamh Clarke; Joanne Lysaght; Narayanasamy Ravi; Dermot O'Toole; Finbar MacCarthy; John V Reynolds; Breandán N Kennedy; Jacintha O'Sullivan
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.379

Review 10.  The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy.

Authors:  Alexis Fong; Amanda Durkin; Hoyun Lee
Journal:  Int J Mol Sci       Date:  2019-01-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.